TheranosticTrials.org
Perspective Therapeutics

Clinical Trial · NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Overview

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor

Perspective Therapeutics

Phase

Phase 1/2

Contacts

ClinicalTrials at Perspectivetherapeutics (CONTACT)

clinicaltrials@perspectivetherapeutics.com

(206) 676-0900

ClinicalTrials.gov

NCT06710756

Drug / Compound

PSV359

Isotope(s):
Target(s):
  • FAP
Ligand Class: Peptides

PSV359

Isotope(s):
Target(s):
  • FAP
Ligand Class: Peptides

Eligibility

Inclusion

  • Progressive disease despite standard therapy or for whom no standard therapy exists
  • * Aged ≥ 18 years
  • Satisfactory organ function as determined by laboratory testing
  • Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1
  • Life expectancy \> 3 months

Exclusion

  • Pregnancy or breastfeeding a child
  • Known brain metastases
  • Active secondary malignancy
  • * Known hypersensitivity to the active agent or any of the excipients
  • Known active or uncontrolled infections requiring ongoing antifungals or antibiotics in the 3 days prior to enrollment

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…